21Shares Files for Injective (INJ) ETF with SEC

21Shares has taken a major step towards bringing the Injective protocol to mainstream investors by filing for an Injective-focused exchange traded fund (ETF) with the Securities and Exchange Commission. This move signals growing institutional interest in Injective, potentially boosting its market visibility and liquidity. The registration was filed on October 20, 2025, with a corresponding SEC Form S-1 document. The filing is notable as increased trading volume and staking activity have already been observed before the announcement.